Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam

Author(s): Chukwuemeka Mbah*, Josephat Ogbonna, Ifeanyi Nzekwe, George Ugwu, Richard Ezeh, Philip Builders, Anthony Attama, Michael Adikwu and Sabinus Ofoefule

Volume 9, Issue 3, 2021

Published on: 29 January, 2021

Page: [177 - 190] Pages: 14

DOI: 10.2174/2211738509666210129151844

Price: $65

Abstract

Background: Enhanced utilization of certain drugs may be possible through the development of alternative delivery forms. It has been observed that NSAIDs have adverse gastrointestinal tract effects such as irritation and ulceration during anti-inflammatory therapy. This challenge may be overcome through nano topical formulations.

Objective: This study aimed to explore the potentials of a transdermal nanovesicular formulation for safe and enhanced delivery of piroxicam (PRX), a poorly water-soluble NSAID.

Methods: Preformulation studies were conducted using DSC and FTIR. Ethosomal nanovesicular carrier (ENVC) was prepared by thin-film deposition technique using Phospholipon® 90 H (P90H) and ethanol and then converted into gel form. The formulation was characterized using a commercial PRX gel as control. Permeation studies were conducted using rat skin and Franz diffusion cell. Samples were assayed spectrophotometrically, and the obtained data was analyzed by ANOVA using GraphPad Prism software.

Results: The preformulation studies showed compatibility between PRX and P90H. Spherical vesicles of mean size 343.1 ± 5.9 nm, and polydispersity index 0.510 were produced, which remained stable for over 2 years. The optimized formulation (PE30) exhibited pseudoplastic flow, indicating good consistency. The rate of permeation increased with time in the following order: PE30 > Commercial, with significant difference (p< 0.05). It also showed higher inhibition of inflammation (71.92 ± 9.67%) than the reference (64.12 ± 7.92%).

Conclusion: ENVC gel of PRX was formulated. It showed potentials for enhanced transdermal delivery and anti-inflammatory activity relative to the reference. This may be further developed as a safe alternative to the oral form.

Keywords: Nanovesicles, ethosomes, thin-film deposition, transdermal delivery, anti-inflammation, piroxicam.

« Previous Next »
Graphical Abstract

[1]
Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of nonsteroidal anti-inflammatory drug prescriptions with kidney disease among active young and middle-aged adults. JAMA Netw Open 2019; 2(2): e187896.
[http://dx.doi.org/10.1001/jamanetworkopen.2018.7896] [PMID: 30768191]
[2]
Katzung BG, Furst DE. Nonsteroidal anti-inflammatory drugs; disease-modifying antirheumatic drugs; nonopioid analgesics; drugs used in gout. Basic and Clinical Pharmacology. 7th ed. Stamford: Appleton and Lange 1998; pp. 579-99.
[3]
Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med 2002; 69(Suppl. 1): SI53-8.
[http://dx.doi.org/10.3949/ccjm.69.Suppl_1.SI53] [PMID: 12086295]
[4]
FDA. FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes 2015. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication
[5]
Lust A, Strachan CJ, Veski P, et al. Amorphous solid dispersions of piroxicam and Soluplus®: Qualitative and quantitative analysis of piroxicam recrystallization during storage. Int J Pharm 2015; 486(1-2): 306-14.
[http://dx.doi.org/10.1016/j.ijpharm.2015.03.079] [PMID: 25843761]
[6]
Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 2009; 98(8): 2549-72.
[http://dx.doi.org/10.1002/jps.21650] [PMID: 19373886]
[7]
Elmowafy M, Samy A, Abdelaziz AE, et al. Polymeric nanoparticles based topical gel of poorly soluble drug: Formulation, ex-vivo and in-vivo evaluation. Beni-Suef Univ J Bas Appl Sci 2017; 6: 184-91.
[http://dx.doi.org/10.1016/j.bjbas.2017.03.004]
[8]
BASF. BASF, Strategies for working with poorly water-soluble APIs. Pharm Tech 2020; 1-29.
[9]
Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine 2015; 10: 975-99.
[http://dx.doi.org/10.2147/IJN.S68861] [PMID: 25678787]
[10]
Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2(1): 35-47.
[http://dx.doi.org/10.1002/wnan.59] [PMID: 20049829]
[11]
Karavelidis V, Giliopoulos D, Karavas E, Bikiaris D. Nanoencapsulation of a water soluble drug in biocompatible polyesters. Effect of polyesters melting point and glass transition temperature on drug release behavior. Eur J Pharm Sci 2010; 41(5): 636-43.
[http://dx.doi.org/10.1016/j.ejps.2010.09.004] [PMID: 20863892]
[12]
Serikawa T, Kikuchi A, Sugaya S, Suzuki N, Kikuchi H, Tanaka K. In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy. J Control Release 2006; 113(3): 255-60.
[http://dx.doi.org/10.1016/j.jconrel.2006.04.001] [PMID: 16793160]
[13]
Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol 2005; 2(1): 67-74.
[http://dx.doi.org/10.1016/j.ddtec.2005.05.003] [PMID: 24981757]
[14]
Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 2005; 66(2): 461-6.
[http://dx.doi.org/10.1016/j.urology.2005.03.052] [PMID: 16040105]
[15]
Barry BW. Breaching the skin’s barrier to drugs. Nat Biotechnol 2004; 22(2): 165-7.
[http://dx.doi.org/10.1038/nbt0204-165] [PMID: 14755286]
[16]
Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65(3): 403-18.
[http://dx.doi.org/10.1016/S0168-3659(99)00222-9] [PMID: 10699298]
[17]
Goindi S, Dhatt B, Kaur A. Ethosomes-based topical delivery system of antihistaminic drug for treatment of skin allergies. J Microencapsul 2014; 31(7): 716-24.
[http://dx.doi.org/10.3109/02652048.2014.918667] [PMID: 24963956]
[18]
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics 2017; 9(2): 12.
[http://dx.doi.org/10.3390/pharmaceutics9020012] [PMID: 28346375]
[19]
Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13(1): 238-52.
[http://dx.doi.org/10.1016/S0022-2836(65)80093-6] [PMID: 5859039]
[20]
Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355(1-2): 307-13.
[http://dx.doi.org/10.1016/j.ijpharm.2007.12.007] [PMID: 18242022]
[21]
Torchilin VP, Weissig V. Liposomes - a practical approach. 2nd ed. Kettering, UK: Oxford University Press 2003; pp. 77-101.
[22]
Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface active agents as observed in the electron microscope. J Mol Biol 1964; 8: 660-8.
[http://dx.doi.org/10.1016/S0022-2836(64)80115-7] [PMID: 14187392]
[23]
Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160(2): 117-34.
[http://dx.doi.org/10.1016/j.jconrel.2012.03.020] [PMID: 22484195]
[24]
Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 2007; 332(1-2): 1-16. a
[http://dx.doi.org/10.1016/j.ijpharm.2006.12.005] [PMID: 17222523]
[25]
Vyas SP, Khatri K, Mishra V. Vesicular carrier constructs for topical immunisation. Expert Opin Drug Deliv 2007; 4(4): 341-8.
[http://dx.doi.org/10.1517/17425247.4.4.341] [PMID: 17683248]
[26]
Hoet PH, Brüske-Hohlfeld I, Salata OV. Nanoparticles - known and unknown health risks. J Nanobiotechnology 2004; 2(1): 12.
[http://dx.doi.org/10.1186/1477-3155-2-12] [PMID: 15588280]
[27]
Mbah CC, Builders PF, Attama AA. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus. Expert Opin Drug Deliv 2014; 11(1): 45-59. a
[http://dx.doi.org/10.1517/17425247.2013.860130] [PMID: 24294974]
[28]
Guterres SS, Alves MP, Pohlmann AR. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007; 2: 147-57.
[http://dx.doi.org/10.1177/117739280700200002] [PMID: 21901071]
[29]
Sigma-Aldrich. Piroxicam. 2020. Available at: https://www.sigmaaldrich.com/catalog/substance/piroxicam
[30]
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3): 413-20.
[http://dx.doi.org/10.1023/A:1016212804288] [PMID: 7617530]
[31]
Jeong D, Choi JM, Choi Y, Jeong K, Cho E, Jung S. Complexation of fisetin with novel cyclosophoroase dimer to improve solubility and bioavailability. Carbohydr Polym 2013; 97(1): 196-202.
[http://dx.doi.org/10.1016/j.carbpol.2013.04.066] [PMID: 23769537]
[32]
Dhage MA, Chhabra GS, Banerjee SK. Development and validation of UV-spectrophotometric method for piroxicam in bulk and pharmaceutical formulations. J Chem Pharm Res 2011; 3(2): 765-79.
[33]
Araújo J, Vega E, Lopes C, Egea MA, Garcia ML, Souto EB. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B Biointerfaces 2009; 72(1): 48-56.
[http://dx.doi.org/10.1016/j.colsurfb.2009.03.028] [PMID: 19403277]
[34]
Mbah CC, Builders PF, Agubata CO, Attama AA. Development of ethosomal vesicular carrier for topical application of griseofulvin: effect of ethanol concentration. J Pharm Investig 2019; 49(1): 27-36.
[http://dx.doi.org/10.1007/s40005-017-0367-z]
[35]
Carter SJ. Jellies formulation: sodium alginate. Cooper and gun’s dispensing for pharmaceutical students. 12th ed. Edinburgh: Churchill Livingstone 1987; pp. 214-8.
[36]
Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm 2008; 363(1-2): 132-8.
[http://dx.doi.org/10.1016/j.ijpharm.2008.06.028] [PMID: 18657601]
[37]
British Pharmacopoeia (BP). Monograph A-Z 1-4. Her Majesty’s stationary office, London: The Pharmaceutical Press 2004.
[38]
Shivanand P, Manish G, Viral D, Jarina F. Transferosomes: a novel approach for transdermal drug delivery. Der Pharm Lett 2009; 1(2): 143-50.
[39]
Aulton ME. Disperse Systems: Pharmaceutics. The Science of Dosage Form Design IS ed. Edinburgh: Churchill Livingstone 2002.
[40]
OECD. OECD test guidelines 404: acute dermal irritation and corrosion. Paris, France 2002.
[41]
Mbah CC, Akuodor GC, Anyalewechi NA, Iwuanyanwu TC, Osunkwo UA. In vivo antiplasmodial activities of aqueous extract of Bridelia ferruginea stem bark against Plasmodium berghei berghei in mice. Pharm Biol 2012; 50(2): 188-94.
[http://dx.doi.org/10.3109/13880209.2011.592537] [PMID: 22235887]
[42]
National Academy of Sciences (NAS). Guide for the care and use of laboratory animals 2010. Available at: grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals_prepub.pdf
[43]
Asuzu IU, Sosa S, Della Loggia R. The antiinflammatory activity of Icacina trichantha tuber. Phytomedicine 1999; 6(4): 267-72.
[http://dx.doi.org/10.1016/S0944-7113(99)80019-1] [PMID: 10589446]
[44]
Okoli CO, Akah PA, Onuoha NJ, Okoye TC, Nwoye AC, Nworu CS. Acanthus montanus: an experimental evaluation of the antimicrobial, anti-inflammatory and immunological properties of a traditional remedy for furuncles. BMC Complement Altern Med 2008; 8: 27.
[http://dx.doi.org/10.1186/1472-6882-8-27] [PMID: 18538006]
[45]
Kenechukwu FC, Attama AA, Ibezim EC, et al. Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. Eur J Pharm Sci 111: 358-75.
[http://dx.doi.org/10.1016/j.ejps.2017.10.002]
[46]
Suresh S, Gunasekaran S, Srinivasan S. Vibrational spectra (FT-IR, FT-Raman), frontier molecular orbital, first hyperpolarizability, NBO analysis and thermodynamics properties of Piroxicam by HF and DFT methods. Spectrochim Acta A Mol Biomol Spectrosc 2015; 138: 447-59.
[http://dx.doi.org/10.1016/j.saa.2014.11.040] [PMID: 25523048]
[47]
Zhang R, Li X, Zhang X. Molecular structure and vibrational spectra of phenobaraitone by density functional theory and ab initio Hartree-Fock calculations. Front Chem China 2011; 6: 358-66.
[http://dx.doi.org/10.1007/s11458-011-0255-4]
[48]
Socrates G. Infrared and raman characteristic group frequencies-tables and charts. 3rd ed. New York: Wiley 2001.
[49]
Roges NPG. A guide to the complete interpretation of the infrared spectra of organic structures. New York: Wiley 1994.
[50]
Chohan ZH, Youssoufi MH, Jarrahpour A, Ben Hadda T. Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives. Eur J Med Chem 2010; 45(3): 1189-99.
[http://dx.doi.org/10.1016/j.ejmech.2009.11.029] [PMID: 20005022]
[51]
Michalska D, Bienko DC, Bienko AJA, Latajaka Z. Density functional, Hartree-Fock, and MP2 studies on the vibrational spectrum of phenol. J Phys Chem 1996; 100: 17786-90.
[http://dx.doi.org/10.1021/jp961376v]
[52]
El-Houssiny AS, Ward AA, Mostafa DM, et al. Drug–polymer interaction between glucosamine sulfate and alginate nanoparticles: FTIR, DSC and dielectric spectroscopy studies. Adv Nat Sci: Nanosci Nanotechnol 2016; 7(2): 1-10.
[53]
Gunasekaran S, Balaji RA, Kumaresan S, Anand G, Srinivasan S. Experimental and theoretical investigations of spectroscopic properties of N-acetyl-5-methoxytryptamine. Can J Anal Sci Spectrosc 2008; 53: 149-62.
[54]
Mbah C, Builders P, Nzekwe I, Kunle O, Adikwu M, Attama A. Formulation and in vitro evaluation of pH-responsive ethosomes for vaginal delivery of metronidazole. J Drug Deliv Sci Technol 2014; 24(6): 565-71.
[http://dx.doi.org/10.1016/S1773-2247(14)50120-7]
[55]
Vrecer F, Vrbinc M, Meden A. Characterization of piroxicam crystal modifications. Int J Pharm 2003; 256(1-2): 3-15.
[http://dx.doi.org/10.1016/S0378-5173(03)00057-7] [PMID: 12695006]
[56]
Vrecer F, Srcic S, Smid-Korbar J. Investigation of piroxicam polymorphism. Int J Pharm 1991; 68: 35-41.
[http://dx.doi.org/10.1016/0378-5173(91)90124-7]
[57]
Chemical Book; Piroxicam: Physical and chemical properties. 2010.Available at:. www.chemicalbook.com/ProductMSDSDetailCB1375282_EN.htm
[58]
Khoee S, Hassanzadeh S, Goliaie B. Effects of hydrophobic drug-polyesteric core interactions on drug loading and release properties of poly(ethylene glycol)-polyester-poly(ethylene glycol) triblock core-shell nanoparticles. Nanotechnology 2007; 18: 175602.
[http://dx.doi.org/10.1088/0957-4484/18/17/175602]
[59]
Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release 1993; 25: 89-98.
[http://dx.doi.org/10.1016/0168-3659(93)90097-O]
[60]
Ghan GA, Lalla JK. Effect of compressional forces on piroxicam polymorphs. J Pharm Pharmacol 1992; 44(8): 678-81.
[http://dx.doi.org/10.1111/j.2042-7158.1992.tb05494.x] [PMID: 1359095]
[61]
Sheth AR, Lubach JW, Munson EJ, Muller FX, Grant DJW. Mechanochromism of piroxicam accompanied by intermolecular proton transfer probed by spectroscopic methods and solid-phase changes. J Am Chem Soc 2005; 127(18): 6641-51.
[http://dx.doi.org/10.1021/ja045823t] [PMID: 15869285]
[62]
Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes-non-ionic surfactant vesicles. J Pharm Pharmacol 1985; 37(12): 863-8.
[http://dx.doi.org/10.1111/j.2042-7158.1985.tb04990.x] [PMID: 2868092]
[63]
Braun-Falco O, Kortung HC, Maibach HI, Eds. Giesbach Conference: liposome Dermatics. Berlin, Heidelberg: Springer-Verlag 1992.
[64]
Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14(2): 101-14.
[http://dx.doi.org/10.1016/S0928-0987(01)00167-1] [PMID: 11500256]
[65]
Liu P, Kurihara-Bergstrom T, Good WR. Cotransport of estradiol and ethanol through human skin in vitro: understanding the permeant/enhancer flux relationship. Pharm Res 1991; 8(7): 938-44.
[http://dx.doi.org/10.1023/A:1015876117627] [PMID: 1924148]
[66]
Chernysheva YV, Babak VG, Kildeeva NR, et al. Effect of the type of hydrophobic polymers on the size of nanoparticles obtained by emulsion-solvent evaporation. Mendeleev Commun 2003; 13: 65-8.
[http://dx.doi.org/10.1070/MC2003v013n02ABEH001690]
[67]
Saito Y, Sato T, Anazawa I. Correlation between distribution of oxyethylene chains of nonionic surfactants and stability of cyclohexane droplets. Colloids Surf 1989; 40: 107-14.
[http://dx.doi.org/10.1016/0166-6622(89)80011-3]
[68]
Nguyen CA, Konan-Kouakou YN, Allemann E, et al. Preparation of surfactant-free nanoparticles of methacrylic acid copolymers used for film coating. AAPS Pharm Sci Tech 2006; 7(3): E54-60.
[http://dx.doi.org/10.1208/pt070363]
[69]
Wood JH, Catacalos G, Lieberman SV. Adaptation of commercial viscometers for special applications in pharmaceutical rheology. II. Severs extrusion rheometer. J Pharm Sci 1963; 52: 375-8.
[http://dx.doi.org/10.1002/jps.2600520414] [PMID: 14001746]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy